Pfizer has announced that it will not launch its Amsparity (adalimumab) biosimilar in Europe, just weeks after the rival to Humira received a formal endorsement from the European Medicines Agency’s Committee for Medicinal Products for Human Use, recommending granting a pan-European marketing authorization.
The CHMP nod puts Amsparity in line for an imminent approval from the European Commission, which is responsible for issuing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?